Renewing Medicines. Restoring Lives.
We repurpose proven molecules with modern science to create targeted therapies for conditions shaped by stress, imbalance, and unmet clinical need.
The Devah Vision
A Focus on Therapeutic Renewal
At Devah Therapeutics, we believe innovation can come from seeing hidden potential in what already exists. Our work begins with proven molecules whose value has been overlooked or underexplored—and continues with rigorous modern science that reveals new paths to improve patient lives.
Through a 505(b)(2)-driven strategy, we accelerate development, reduce clinical risk, and bring renewed clarity to medicines that deserve a second chance.
Our goal is simple:
restore resilience, restore balance, restore quality of life.
Our Lead Program:
A unique chemistry estate
Re-examining and Extending Clinical Benefit
We are revitalizing a chemistry estate with a 40+ year international history of safe use. Its unique pharmacologic profile positions it for modern therapeutic re-evaluation across multiple stress-related and metabolic conditions:
-
Targeting dysregulated stress-axis biology and maladaptive neural signaling.
-
Exploring modulation of thermoregulatory and anxiety-linked neurocircuits.
-
Leveraging evidence of uric acid–lowering effects through metabolic regulation pathways.
Why Repurpose?
Smarter Pathways to Proven Therapies
The 505(b)(2) regulatory pathway allows Devah to build on existing safety and pharmacology data, resulting in:
Faster development timelines
Reduced clinical and financial risk
Clearer mechanistic hypotheses
Greater probability of success
Repurposing is not a shortcut—it is a strategy.
By bringing modern tools to well-characterized molecules, we create opportunities for meaningful impact where traditional drug discovery has struggled.
The Science Behind Renewal
Mechanism Matters
Re-examining and Extending Clinical Benefit
Our research focuses on the interconnected biology of stress, thermoregulation, and metabolic imbalance. By examining pathways including PDE inhibition, HPA-axis modulation, and neuro-molecular resilience, we aim to develop therapies that support recovery rather than suppress symptoms.
At Devah, renewal is both scientific and human:
restoring regulation, restoring function, restoring lives.
About Devah Therapeutics
A Company Built on Second Chances
Devah Therapeutics was founded to unlock new value in overlooked medicines, applying contemporary science to reveal their true therapeutic potential. We are committed to advancing safe, effective, and accessible treatments for patients whose daily lives are disrupted by conditions with few satisfying options.
Our name reflects our mission: Devah—a modern reimagining of “two,” symbolizing renewal, duality, and a second chance to make a difference.
BRIAN SPEICHER
Founder & Chief Executive Officer, Devah Therapeutics
Brian Speicher is a biotechnology executive with more than 25 years of experience advancing CNS therapeutics, repurposed drug programs, and translational clinical strategies across emerging biotechs, global pharma, and CRO environments. He is the CEO and founder of Devah Therapeutics, where he is leading the development of a unique chemistry estate with a PDE-modulating and HPA-axis–stabilizing profile.
-
Brian’s career has been defined by a consistent focus on unlocking therapeutic value hidden inside neglected or underdeveloped molecules. He has led or contributed to CNS repurposing and clinical development programs at Vela Pharmaceuticals, Krele Pharmaceuticals, Tonix Pharmaceuticals, Eisai Medical Research, and SCIREX—organizations where (re)development, mechanism refinement, and pathway (re)construction were core to the work. His experience spans from early-stage hypothesis generation through discovery and characterization, efficient nonclinical strategy, Phase I–III clinical execution, and 505(b)(2) regulatory navigation.
A former venture-studio operator, Brian also spent five years leading innovation and commercialization strategy for the Desert Research Institute and served as Director & President of Desert Research Corporation, where he built a playbook for forming and capitalizing institutional spinouts. He founded Tu Biomics, raising multimillion-dollar seed capital, negotiating IP licenses, and advancing products from lab characterization through field trials.
This ecosystem leadership experience gives Brian a strategic advantage as a biotech CEO: a deep understanding of IP development, asset evaluation, partnership design, and early-stage venture formation, all applied to a CNS therapeutic platform that benefits from disciplined capital use and rigorous translational positioning.
Brian holds an MBA from the MIT Sloan School of Management, an MPH in Epidemiology and Data Science from Johns Hopkins University, and dual BSc degrees from Penn State University.
He brings to Devah Therapeutics the combination of clinical development credibility, scientific strategy, and entrepreneurial operational leadership, with a mission to turn overlooked science into therapeutics with meaningful patient impact.
Contact / Investors
Connect With Devah
Partnerships & Scientific Collaborations
We welcome collaborations with clinicians, researchers, and organizations aligned with advancing therapies for stress-related or metabolic disorders.
Devah is actively exploring partnerships and capital strategies to advance our lead program through key milestones.